Market Cap 316.98M
Revenue (ttm) 129.42M
Net Income (ttm) 17.38M
EPS (ttm) N/A
PE Ratio 21.95
Forward PE 17.87
Profit Margin 13.43%
Debt to Equity Ratio 0.00
Volume 1,211,300
Avg Vol 1,271,266
Day's Range N/A - N/A
Shares Out 79.64M
Stochastic %K 7%
Beta 2.17
Analysts Strong Sell
Price Target $11.50

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, in...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
CarpSlayer
CarpSlayer May. 13 at 11:55 AM
$NAGE - Inside the NAD for Health Conference in Copenhagen: Key Takeaways from the World's Leading NAD+ Researchers https://www.aboutnad.com/blogs/blog/inside-the-nad-for-health-conference-in-copenhagen-key-takeaways-from-the-worlds-leading-nad-researchers
0 · Reply
tymtested
tymtested May. 13 at 1:23 AM
$NAGE investors are being conditioned to not hold through quarterly reports.
0 · Reply
tymtested
tymtested May. 13 at 1:21 AM
$NAGE ER was solid but not explosive, so in the shadow of high tech, investors take their money to potentially explosive stocks and NAGE has to wait until the next catalyst.
0 · Reply
theDIOyears
theDIOyears May. 12 at 10:33 PM
$NAGE what's the reason for the fall? Income generation?
2 · Reply
wycliff
wycliff May. 11 at 9:26 PM
$NAGE https://x.com/davidasinclair/status/2053940295318819207?s=10
0 · Reply
wycliff
wycliff May. 11 at 9:26 PM
0 · Reply
wycliff
wycliff May. 11 at 6:44 PM
$NAGE https://www.linkedin.com/posts/reminder-tomorrow-may-12-niagen-bioscience-share-7459666005120876544-Fbb3?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
Cello69
Cello69 May. 11 at 5:59 PM
$NAGE Adding here
1 · Reply
fgmmiami
fgmmiami May. 11 at 3:35 PM
$NAGE https://m.investing.com/news/analyst-ratings/niagen-bioscience-stock-price-target-lowered-to-11-by-hc-wainwright-93CH-4676091?ampMode=1
0 · Reply
wycliff
wycliff May. 11 at 3:02 PM
$NAGE https://cdn.shopify.com/s/files/1/0705/7024/6332/files/State_of_the_Science_Reproductive_Health_V6.pdf?v=1760403780&utm_source=Klaviyo&utm_medium=email&utm_campaign=03_Reproductive_Health&_kx=WWbF7eJ6CuVQl9qPMAU1-RMSCvCc10STMTFmsv1BVyX_jkY2tOtFuwyaawNr6RyR.Y9JRX8
0 · Reply
Latest News on NAGE
Niagen Bioscience reports Q1 EPS 7c, consensus 6c

2026-05-07T01:51:30.000Z - 6 days ago

Niagen Bioscience reports Q1 EPS 7c, consensus 6c


Niagen Bioscience sees 2026 sales growth 10%-15%

2026-05-07T01:50:48.000Z - 6 days ago

Niagen Bioscience sees 2026 sales growth 10%-15%


Niagen Bioscience Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 6 days ago

Niagen Bioscience Earnings Call Transcript: Q1 2026


Niagen Bioscience launches Niagen Plus telehealth plarform

2026-05-04T13:07:08.000Z - 8 days ago

Niagen Bioscience launches Niagen Plus telehealth plarform


Niagen Bioscience increases share repurchase program to $20M

2026-03-19T12:50:32.000Z - 7 weeks ago

Niagen Bioscience increases share repurchase program to $20M


Niagen Bioscience to Present at the 38th Annual ROTH Conference

Mar 18, 2026, 8:32 AM EDT - 7 weeks ago

Niagen Bioscience to Present at the 38th Annual ROTH Conference


Niagen Bioscience up 39% at $6.88 after Q4 results and guidance

2026-03-04T21:45:21.000Z - 2 months ago

Niagen Bioscience up 39% at $6.88 after Q4 results and guidance


Niagen Bioscience Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 2 months ago

Niagen Bioscience Earnings Call Transcript: Q4 2025


Niagen Bioscience reports Q4 EPS 5c, consensus 2c

2026-03-04T21:11:47.000Z - 2 months ago

Niagen Bioscience reports Q4 EPS 5c, consensus 2c


Niagen Bioscience secures new patent for nicotinamide riboside

2026-02-25T13:45:39.000Z - 2 months ago

Niagen Bioscience secures new patent for nicotinamide riboside


Niagen Bioscience Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Niagen Bioscience Earnings Call Transcript: Q3 2025


Niagen Bioscience Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Niagen Bioscience Earnings Call Transcript: Q2 2025


Niagen Bioscience Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q1 2025


ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 1 year ago

ChromaDex to Present at the 37th Annual Roth Conference


Niagen Bioscience Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q4 2024


CarpSlayer
CarpSlayer May. 13 at 11:55 AM
$NAGE - Inside the NAD for Health Conference in Copenhagen: Key Takeaways from the World's Leading NAD+ Researchers https://www.aboutnad.com/blogs/blog/inside-the-nad-for-health-conference-in-copenhagen-key-takeaways-from-the-worlds-leading-nad-researchers
0 · Reply
tymtested
tymtested May. 13 at 1:23 AM
$NAGE investors are being conditioned to not hold through quarterly reports.
0 · Reply
tymtested
tymtested May. 13 at 1:21 AM
$NAGE ER was solid but not explosive, so in the shadow of high tech, investors take their money to potentially explosive stocks and NAGE has to wait until the next catalyst.
0 · Reply
theDIOyears
theDIOyears May. 12 at 10:33 PM
$NAGE what's the reason for the fall? Income generation?
2 · Reply
wycliff
wycliff May. 11 at 9:26 PM
$NAGE https://x.com/davidasinclair/status/2053940295318819207?s=10
0 · Reply
wycliff
wycliff May. 11 at 9:26 PM
0 · Reply
wycliff
wycliff May. 11 at 6:44 PM
$NAGE https://www.linkedin.com/posts/reminder-tomorrow-may-12-niagen-bioscience-share-7459666005120876544-Fbb3?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
Cello69
Cello69 May. 11 at 5:59 PM
$NAGE Adding here
1 · Reply
fgmmiami
fgmmiami May. 11 at 3:35 PM
$NAGE https://m.investing.com/news/analyst-ratings/niagen-bioscience-stock-price-target-lowered-to-11-by-hc-wainwright-93CH-4676091?ampMode=1
0 · Reply
wycliff
wycliff May. 11 at 3:02 PM
$NAGE https://cdn.shopify.com/s/files/1/0705/7024/6332/files/State_of_the_Science_Reproductive_Health_V6.pdf?v=1760403780&utm_source=Klaviyo&utm_medium=email&utm_campaign=03_Reproductive_Health&_kx=WWbF7eJ6CuVQl9qPMAU1-RMSCvCc10STMTFmsv1BVyX_jkY2tOtFuwyaawNr6RyR.Y9JRX8
0 · Reply
CarpSlayer
CarpSlayer May. 11 at 1:08 PM
$NAGE Marketers say NAD+ pills and infusions can boost longevity. What's the evidence? Greater awareness inevitably leads to more scrutiny. https://www.npr.org/2026/05/11/nx-s1-5813664/nad-infusions-supplements-longevity-science
1 · Reply
wycliff
wycliff May. 10 at 3:12 PM
$NAGE https://www.instagram.com/reel/DYKYxMuuhLA/?igsh=MXI0bGo3bXp0cXFobA==
0 · Reply
wycliff
wycliff May. 10 at 4:13 AM
$NAGE https://g.co/gemini/share/f4f346826d2e
0 · Reply
MattManzanita
MattManzanita May. 8 at 11:54 PM
$NAGE Niagen Bio making efforts to get Niagen Plus approved internationally: AI Overview Yes, Niagen Bioscience (formerly ChromaDex) is actively expanding the global footprint of its patented nicotinamide riboside (NR) products, including the Niagen Plus intravenous (IV) and injectable formulations, into international markets.While Niagen Plus currently operates as a premium service in U.S. FDA-registered 503B outsourcing facilities and via telehealth, the company is leveraging its global IP portfolio to expand this footprint.Key International Expansion and Regulatory Efforts:Cruise Ship Expansion: Niagen Plus has entered into partnerships to make Niagen IV services available through OneSpaWorld onboard cruise ships. This rollout provides a mechanism for Niagen Plus to reach consumers internationally outside the immediate U.S. clinical setting.European Clinical Development: In July 2025, Niagen Bioscience entered a licensin....
0 · Reply
MattManzanita
MattManzanita May. 8 at 11:29 PM
$NAGE The number of clinics offering Niagen plus is up a bit to 1,272.
0 · Reply
Jimgym
Jimgym May. 8 at 8:17 PM
$NAGE stock is getting crushed…or is that what they want you to think? Meanwhile vanguard seems to have taken a few million more shares and Tieton took a few hundred k Institutional ownership currently reported at 38.8M which is the highest ever. End of next week should round up Q1 holding reports. https://fintel.io/so/us/nage
1 · Reply
StreetwiseReports
StreetwiseReports May. 8 at 7:23 PM
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results https://ow.ly/2b7F50YWIQo Niagen Bioscience Inc. ( $NAGE ) reports a 3% increase in total net sales to US$31.5 million for the first quarter. Read why analysts recommend this stock in a rapidly expanding market.
0 · Reply
MattManzanita
MattManzanita May. 8 at 5:37 PM
$NAGE This is why some form of NR might replace the currently approved drugs for diseases like Frederich's Ataxia eventually. Note the recent clinical trial indicating that NR worked regarding that disease, and without significant side effects. And Skylars sold it for $7.3 billion $. AI "Yes, the FDA-approved drug for Friedreich’s ataxia, Skyclarys (omaveloxolone), has adverse side effects, though it is generally well-tolerated. The most common side effects include elevated liver enzymes, headache, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pai Key Safety Information for Skyclarys: Liver Enzyme Elevations: Elevated liver enzymes (ALT/AST) are common, indicating potential liver injury. These usually occur within the first 12 weeks, are typically manageable, and often reversible. Heart Function Marker (BNP): Skyclarys can cause an increase in B-type natriuretic peptide Cholesterol Levels: Increased cholesterol levels Gastrointestinal Issues: Nausea, diarrhea, etc.
0 · Reply
wycliff
wycliff May. 8 at 5:14 PM
$NAGE https://www.linkedin.com/posts/nage-niagen-nr-share-7458561446084452352-wsSz?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
focafoca99
focafoca99 May. 8 at 1:14 PM
$NAGE participates in the 31st Sohn Investment Conference and Benchmark Consumer One-On-One Conference in May.
0 · Reply
wycliff
wycliff May. 8 at 1:09 PM
$NAGE https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-Announces-Participation-in-Upcoming-Investor-Conferences/default.aspx
1 · Reply
MattManzanita
MattManzanita May. 8 at 3:44 AM
$NAGE Reading betwen the lines, I think NAGE is going for accelerated approval for Ataxia-T. Fried mentioned planning to engage a COA consultant. That is done when it is time to apply for drug approval. The Phase 2 A-T results were favorable. Drugs with Rare Pediatric Disease Designation Key Connections Between RPDD and Accelerated ApprovalTargeted Incentives: RPDD qualifies a drug for a Priority Review Voucher (PRV) upon approval, which can be used to accelerate the review of a future, different drug application to six months.Unmet Need Requirement: Because RPDD drugs must treat "serious or life-threatening" diseases, they are prime candidates for the FDA's accelerated approval pathway, which allows for approval based on surrogate endpoints rather than full clinical trials, say ProPharma and EveryLife Foundation.High Frequency of Use: Data shows a significant overlap, with many rare disease approvals utilizing one or more expedited programs. (continued)
4 · Reply